Direct Answer
Cardiometabolic drug companies develop treatments for diabetes, obesity, cholesterol, hypertension and heart failure. These are large chronic markets where outcome trials, payer coverage and manufacturing supply drive results.
Industry Overview
Cardiometabolic Pharmaceuticals sits within the health care sector. The first numbers to compare across companies here are prescription volume and net price, share of key drug classes and late-stage trial readouts. The outside forces that move them are listed under Primary Macro Drivers.
Key Industry Metrics
- Prescription volume and net price: Number of prescriptions filled and the price actually received after rebates and discounts. Volume growth with falling net price is common in crowded classes, so both are needed to read revenue.
- Share of key drug classes: Portion of prescriptions in a class, such as incretins or statins, going to a company's drugs. Share gains show competitive strength, and losses to newer entrants show up here before they reach revenue.
- Late-stage trial readouts: Results from large phase 3 and outcome trials testing new drugs or new uses. Positive cardiovascular outcome data can widen coverage, while a miss or safety finding can reduce a drug's prospects.
- Supply capacity: Manufacturing output available for injectable and other drugs. In large chronic markets, constrained supply can cap sales even when demand and coverage are strong.
- Patent expiry timeline: Dates when exclusivity on key drugs ends and generics may enter. Older cardiometabolic drugs lose most revenue to generics after expiry, so the timeline shows how long current earnings are protected.
Primary Macro Drivers
- Obesity and diabetes prevalence: More people with diabetes and obesity widens the pool of patients who can be treated, supporting prescription volume for the drug classes that target them.
- Payer coverage decisions: Whether insurers cover a drug, and on what terms, decides how many patients can actually fill it, so coverage shifts prescription volume and net price.
- Cardiovascular outcome data: Trials showing that a drug lowers heart attacks or strokes can widen its label and payer coverage, lifting the volume of prescriptions over time.
- Manufacturing capacity for injectable drugs: Injectable drugs need specialized plants, so supply capacity caps how many patients can be started even if demand is strong, and shortages limit prescriptions.
Major Risks
- Price controls and rebates: Government price negotiation or higher rebates cut the net price received per prescription; watch the gap between list price and net price in filings.
- Generic entry on older drugs: When patents lapse, cheaper generics take much of the volume and net price falls quickly; watch the patent expiry timeline against sales of each older drug.
- Safety findings: New safety findings can lead to warnings, label restrictions or reduced prescribing; watch regulatory communications and long-term trial data for the drugs.
- Crowded competition among a few large classes: Few large classes hold most of the market, so a rival's stronger data or lower price can shift share fast; watch share of key drug classes and pricing moves.
Industry Characteristics
| Characteristic | Profile |
|---|---|
| Cyclicality | Defensive |
| Capital Intensity | Medium |
| Regulatory Intensity | High |
| Industry Maturity | Growth |
| Geographic Importance | U.S. / Global |
Companies Associated with Cardiometabolic Pharmaceuticals
The SEC's Standard Industrial Classification has no code that describes cardiometabolic pharmaceuticals as a group, so there is no complete list of its filers. The companies below come from Swoopr's SEC dataset and have operations in or next to the industry. Each is classified by the SEC under its own main business.
| Company | SEC classification | Revenue | Growth | Net margin | Year |
|---|---|---|---|---|---|
| Eli Lilly & Co | Pharmaceutical Preparations | $65.2 billion | 44.7% | 31.7% | FY 2025 |
| Amgen Inc | Biological Products, (No Diagnostic Substances) | $36.8 billion | 10.0% | 21.0% | FY 2025 |
Source: each company's own annual report as filed with the SEC (XBRL data), figures in U.S. dollars. Listing here describes a business relationship to the industry, not a recommendation. To find more companies, use the company directory and the health care hub.
Where to Go Next
The Cardiometabolic Pharmaceuticals guide describes how the industry earns money, what to measure and what can go wrong. To see how it compares, read the neighbouring industries in the same sector, then apply the same checks to a specific company.
More in Health Care
- Health Care sector overview
- Cardiovascular Devices
- Biotechnology
- Care Delivery
- Biosimilars
- Cell Therapy
- Biopharma Manufacturing Equipment
- Clinical-Stage Biotechnology
- Bioinformatics
Put it to work
Frequently Asked Questions
What are the main KPIs for the Cardiometabolic Pharmaceuticals industry?
Key performance indicators for the Cardiometabolic Pharmaceuticals industry include: Prescription volume and net price, Share of key drug classes, Late-stage trial readouts, Supply capacity, Patent expiry timeline. Which matter most depends on the company's model, so compare them across several companies rather than relying on one.
How cyclical is the Cardiometabolic Pharmaceuticals industry?
The Cardiometabolic Pharmaceuticals industry is generally defensive, meaning demand tends to remain relatively stable regardless of the economic cycle. Companies in this space can provide portfolio stability during recessions, though growth may lag in strong expansions.
What are the biggest risks in the Cardiometabolic Pharmaceuticals industry?
The primary risks for Cardiometabolic Pharmaceuticals companies include: Price controls and rebates, Generic entry on older drugs, Safety findings, Crowded competition among a few large classes. Investors should assess each company's exposure to these factors and its track record of navigating them.